{
    "success": true,
    "data": {
        "leverage": false,
        "derivatives": true,
        "swaps": true,
        "inverse": false,
        "replication_method": "physical",
        "ucits": true,
        "type": "ETF",
        "complex_factors": [
            "Derivative use for investment exposure",
            "Counterparty risk from derivatives",
            "Specialized and scored index methodology"
        ],
        "classification": "complex",
        "supporting_data": "The Fund is a UCITS ETF and primarily uses physical replication. However, the Key Investor Information Document (KID) states that the Fund 'may also invest in... financial derivative instruments ('FDIs') (i.e. investments the prices of which are based on the companies contained in the Index and/or such other 'technology' companies)'. This indicates that FDIs are used to achieve investment exposure, which goes beyond typical efficient portfolio management (EPM) and makes them an inherent element of the strategy. The KID explicitly mentions 'Third party service providers (such as counterparties entering into FDIs with the Fund or the Companyu2019s depositary) may go bankrupt and fail to pay money due to the Fund or return property belonging to the Fund', confirming associated counterparty risk. Per the provided MiFID II Complexity Assessment Rules, 'If any element of Contingent Bonds or any Swap usage is identified then the 'classification' must be 'complex''. While 'swaps' are not explicitly named, the description of FDI usage for investment exposure and the explicit mention of counterparty risk are strong indicators of swap-like instruments or derivatives that introduce similar complexities and risks for retail investors. The rule also states that 'Even limited derivative use for EPM can sometimes be flagged as complex by regulators (e.g., ESMA), especially if it introduces counterparty risk'. Given the confirmed counterparty risk from FDIs, this contributes to complexity. Additionally, the ROBO Globalu00ae Healthcare Technology and Innovation Index TR, while transparently described, uses a specialized scoring methodology based on factors like revenue from healthcare technology, levels of investment, and market positioning, which can add a layer of conceptual complexity for the average retail investor compared to a simple market-capitalization-weighted index. The Fund also has a high risk rating (7/7), driven by market and sector-specific risks, which, while not directly a complexity factor in isolation, further highlights the need for a clear understanding of the investment. Therefore, the use of FDIs for investment exposure with associated counterparty risk, despite primary physical replication, leads to a 'complex' classification."
    }
}